Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated a biotechnology company engages in developing and commercializing therapies for treating cystic fibrosis The company markets SYMDEKOSYMKEVI ORKAMBI and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation Its pipeline includes VX864 for the treatment of AAT deficiency which is in Phase 2 clinical trial VX147 for the treatment of APOL1mediated focal segmental glomerulosclerosis or FSGS and other serious kidney diseases which is in Phase 2 clinical trial VX 880 treatment for Type 1 Diabetes which is in Phase 12 clinical trial VX548 a NaV18 inhibitor for treatments of acute neuropathic musculoskeletal pain which is in Phase 2 clinical trial and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial The company sells its products primarily to specialty pharmacy and specialty distributors in the United States as well as specialty distributors and retail chains and hospitals and clinics internationally It has collaborations with Affinia Therapeutics Inc Arbor Biotechnologies Inc CRISPR Therapeutics AG Kymera Therapeutics Inc Mammoth Biosciences Inc Moderna Inc Obsidian Therapeutics Inc and Skyhawk Therapeutics Inc as well as Ribometrix Inc Genomics plc Merck KGaA Darmstadt Germany and XChem Inc Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston Massachusetts